IAN Angel Fund leads ₹8 crore funding round in Biodimension
IAN Angel Fund, the evergreen fund of IAN Group, has led a ₹8 crore funding round in Biodimension, a Bengaluru-based life sciences company specialising in New Approach Methodologies (NAMs) and tissue engineering. Existing investor Campus Angels Network, Dr. Sampath Srisailam, also participated in the round along with other angel investors like Mr. Aaryan Baid.
The fresh capital will be utilised to accelerate product development, expand laboratory infrastructure, strengthen scientific and commercial teams, and drive product commercialisation in India and international markets.
Founded by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension is building biofabricated human tissue and organoid models as ethical, human-relevant alternatives to animal testing. The company’s solutions help pharmaceutical, biotechnology, and cosmetic companies generate more predictive human data, enabling faster and more reliable decision-making across research, safety testing, and product development.
IAN Angel Fund’s investment in Biodimension comes at a pivotal time for the life sciences industry. Global regulators are accelerating the adoption of human-relevant testing technologies, while pharmaceutical and biotechnology companies are actively seeking more predictive alternatives to animal testing. With nearly 90% of drugs failing during human clinical development despite succeeding in animal studies, the need for better research models has never been greater. Biodimension has built a differentiated platform that combines scientific innovation, commercial validation, and cost-effective local manufacturing, making it well-positioned to capitalize on this structural shift.
Despite being one of the world’s largest pharmaceutical manufacturing hubs, India remains dependent on imported human tissue models and testing systems. Biodimension is addressing this gap through locally developed and manufactured alternatives that align with emerging global regulatory standards while offering significantly lower costs and faster access for researchers and industry.
BioDimension’s portfolio includes BioDEpi, a reconstructed human epidermis model for safety and toxicity testing; BioDFT, a full-thickness human skin model that closely replicates real skin biology; BioDPigma, a pigmented skin model designed for advanced dermatological and cosmetic research; the Pan-Cancer Tumour Microenvironment (TME) Biobank, which supports cancer drug discovery and translational research; and BaaS (Bioassay as a Service), enabling pharmaceutical, biotechnology, and cosmetic companies to access validated human-relevant testing solutions on demand.
Manojkumar S., Co-founder & CEO, Biodimension, said, “This funding marks a pivotal moment in our journey to redefine drug testing and healthcare innovation. The support from IAN and our co-investors will allow us to accelerate the development and commercialisation of our 3D tumour microenvironment platform and expand our BioDEpi skin model suite. Our goal is to provide pharmaceutical and cosmetic industries with advanced testing platforms that offer more reliable, human-relevant data. This investment is a strong validation of our belief that India is ready to lead in next-generation, human-relevant biology. We are building not just products, but an entire infrastructure for predictive, ethical, and scientifically superior testing, one that will serve the Indian pharma and biotech ecosystem as well as global partners.”
Biodimension has already established collaborations with pharmaceutical companies, biotechnology firms, research institutions, and contract research organisations across India and Singapore. The company is witnessing growing interest in human-relevant testing platforms as global industries increasingly seek alternatives that improve predictability while meeting evolving regulatory requirements.
The global in vitro toxicology testing market is valued at approximately USD 14 billion and is expected to grow steadily, driven by increasing pharmaceutical R&D investments, regulatory pressure to reduce animal testing, and rising adoption of advanced 3D cell culture technologies. This presents a significant opportunity for indigenous platforms that can serve both domestic and global demand.
Looking ahead, Biodimension plans to expand its Pan-Cancer Tumour Microenvironment Biobank, introduce additional oncology and immunotherapy research models, and strengthen its Bioassay-as-a-Service platform. The company also aims to expand across Southeast Asia while building partnerships in Europe, the United States, and Japan.
About Biodimension
Biodimension Technology Pvt. Ltd. is a Bengaluru-based life sciences company specialising in New Approach Methodologies (NAMs) and tissue engineering. It develops biofabricated human tissue and organoid models as ethical, human-relevant alternatives to animal testing. Its engineered tissues (e.g., skin, cancer models) help pharmaceutical and cosmetic companies accelerate drug discovery and safety testing with more reliable human data. BioDimension’s product portfolio includes BioDEpi (reconstructed human epidermis model), BioDFT (Full Thickness Skin), BioDPigma (pigmented skin model), the Pan-Cancer Tumour Microenvironment (TME) Biobank, and BaaS (Bioassay as a Service); enabling pharma, biotech, and cosmetic companies to conduct safer, faster, and more predictive testing.
About IAN Angel Fund
IAN Angel Fund, the evergreen fund of IAN Group, is a SEBI-registered Category I AIF and part of India’s leading early-stage investment platform, which pioneered angel investing in the country. Today, IAN invests through its Angel Fund and venture capital funds, backed by a network of approximately 500 investors, including iconic entrepreneurs and industry leaders from India and overseas. The platform enables founders to raise capital from ₹50 lakh to ₹50 crore as they scale, while offering investors a diversified early-stage portfolio across both emerging and growth-stage startups.
About IAN Group
IAN Group is India’s largest horizontal platform for early-stage investments, comprising the IAN Angel Fund, BioAngels, and a series of SEBI-registered venture capital funds, including the US$100 million IAN Alpha Fund. IAN supports entrepreneurs with capital, mentoring by experienced founders, and access to global markets. Forbes has recognised IAN as one of the most iconic business and economic developments of Independent India over the last 75 years, alongside institutions such as LIC, NASSCOM, the RBI, and Naukri.com.